Unique ID issued by UMIN | UMIN000007028 |
---|---|
Receipt number | R000008293 |
Scientific Title | Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy |
Date of disclosure of the study information | 2012/01/06 |
Last modified on | 2012/01/06 18:03:36 |
Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy
Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy
Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy
Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy
Japan |
Glaucoma
Ophthalmology |
Others
NO
The objective of this study is to assess
the efficacy of changing to Travoprost/Timolol fixed combination in patients with glaucoma or ocular hypertension,who can not achieve target IOP while on their current IOP-lowering
monotherapy(travoprost, tafluprost,
latanoprost, bimatoprost).
Safety,Efficacy
Confirmatory
Not applicable
Efficacy
IOP value;IOP-lowering effect from baseline(reduced value;reduction rate%)
Safety
1.Ocular safety assessment:
Conjunctival hyperemia,adverse events
2.Systemic safety assessment:
Blood pressure,the pulse,adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Travoprost/Timolol fixed combination ophthalmic solution for 3 months
20 | years-old | <= |
Not applicable |
Male and Female
1.Age at the time of the agreement 20 years old or older.
2.Gender and outpatient or the hospitalization are no object.
3.Must have been treated monotherapy with PGAs for 3 months or longer for the study eye, by the time of baseline examinations.
4.Patients who are judged to require the switch of Duotrav with be not able to achieve target IOP as on their current IOP-lowering monotherapy
1.Complications with chronic or recurrent uveitis,scleritis,or corneal herpes.
2.History of ocular trauma or intraocular conventional surgery or laser ocular surgery in the study eye within 3 months before baseline examinations.
3.Any abnormality preventing reliable applanation tonometer in the study eye.
4.Known medical history of allergic to PGAs or beta-blockers. 5.Contraindication of beta-blockers
6.Patients using an IOP-lowering drug other than those to be used in the study.
7.Patients using systemic administration of an oral CAI (Diamox,etc.)
8.Patient having serious eyes complications
9.Women who are pregnant or lactating
10.Severe dementia
11.Patients who are judged to be inappropriate for participation in the study for other reason by the doctor in charge.
180
1st name | |
Middle name | |
Last name | Keiji Yoshikawa |
Yoshikawa Eye Clini
Ophthalmology Director
1-3-1 Nakamachi Machida-city Tokyo
042-739-0781
1st name | |
Middle name | |
Last name | Tadashi Nakano |
The Jikei University
Ophthalmology
3-19-18Nishishinbashi minato-ku
03-3433-1111
tnakano@jikei.ac.jp
I.CHANGE study group
Japan Association of Health Service Foundation
Non profit foundation
Japan
NO
吉川眼科クリニック(東京都)、東北大学(宮城県)、南松山病院(愛媛県)、東京慈恵会医科大学(東京都)
2012 | Year | 01 | Month | 06 | Day |
Unpublished
Enrolling by invitation
2011 | Year | 06 | Month | 21 | Day |
2011 | Year | 12 | Month | 01 | Day |
2012 | Year | 12 | Month | 01 | Day |
2013 | Year | 01 | Month | 01 | Day |
2013 | Year | 02 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
2012 | Year | 01 | Month | 06 | Day |
2012 | Year | 01 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008293